In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
The in vitro activity of decaplanin (formerly M86-1410), a novel glycopeptide antimicrobial agent, was tested against 169 gram-positive bloodstream isolates from patients at the University of Iowa Hospitals and Clinics and 12 selected vancomycin-resistant strains. Enterococcus faecalis, E. faecium, Staphylococcus aureus, streptococci, bacilli, corynebacteria, and listeria were inhibited by decaplanin (MICs for 90% of the strains tested [MIC90s], 0.12 to 4 micrograms/ml). However, some rarely isolated and selected Enterococcus sp. populations had a MIC90 of 16 micrograms/ml, and S. haemolyticus strains had a MIC90 of 8 micrograms/ml. These in vitro results suggest that decaplanin may be useful against most gram-positive strains, even though some Enterococcus species and coagulase-negative staphylococci were potentially resistant (MICs, greater than or equal to 8 micrograms/ml).
Sanchez
M L
ML
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
Wenzel
R P
RP
Jones
R N
RN
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D006020:Glycopeptides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology; D017334:Teicoplanin; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D010456:Peptides, Cyclic; C076135:decaplanin; D017334:Teicoplanin; D014640:Vancomycin; D000667:Ampicillin